home / stock / itos / itos news


ITOS News and Press, iTeos Therapeutics Inc. From 08/23/23

Stock Information

Company Name: iTeos Therapeutics Inc.
Stock Symbol: ITOS
Market: NASDAQ
Website: iteostherapeutics.com

Menu

ITOS ITOS Quote ITOS Short ITOS News ITOS Articles ITOS Message Board
Get ITOS Alerts

News, Short Squeeze, Breakout and More Instantly...

ITOS - ITOS, ADTX and LASE among mid-day movers

2023-08-23 13:11:49 ET Gainers: VCI Global Limited ( VCIG ) +107% . Mercurity Fintech Holding ( MFH ) +44% . Apellis Pharmaceuticals ( APLS ) +32% . iTeos Therapeutics ( ITOS ) +27% . Hitek Global ( HKIT ) +26% . Aditxt ( A...

ITOS - ITOS, APLS and TIVC among top healthcare movers

2023-08-23 10:12:08 ET More on Healthcare sector XLV Vs. VHT: A Head-To-Head Healthcare ETF Comparison XLV: The Powerhouse ETF Driving Health And Wealth BlackRock spotlights healthcare as an opportunity with recession talks in the air BofA experiences its thi...

ITOS - Turkcell Iletisim Hizmetleri, Apellis Pharmaceuticals, Manchester United among premarket gainers' pack

2023-08-23 08:47:02 ET VCI Global ( VCIG ) +61% after announces visionary collaboration with Microsoft Azure OpenAI . iTeos Therapeutics ( ITOS ) +37% in reaction as Roche send anti-TIGIT developers higher after mistakenly-released cancer drug data . Arcus ...

ITOS - Roche send anti-TIGIT developers higher after mistakenly released cancer drug data

2023-08-23 07:31:22 ET More on Roche Roche drives rival anti-TIGIT developers higher after cancer drug data Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender Roche, Alnylam in pact for blood pressure candidate Roivant report...

ITOS - iTeos Therapeutics GAAP EPS of -$0.96

2023-08-08 08:02:19 ET iTeos Therapeutics press release ( NASDAQ: ITOS ): Q2 GAAP EPS of -$0.96. The company’s cash, cash equivalents, and investments position was $677.5 million as of June 30, 2023, as compared to $791.9 million as of June 30, 2022. For furth...

ITOS - iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates

– Preparation underway with GSK for Phase 3 registrational studies evaluating belrestotug and dostarlimab combination – Initiated enrollment in Phase 1 trial of EOS-984, a first-in-class program targeting a new mechanism of action in the adenosine pathway &...

ITOS - Forensic Value Mid-Year Selections: Highest Positive And Negative Scoring Stocks For July 2023

2023-07-10 04:56:16 ET Summary The new July 2023 selections are the current top positive/negative forensic stocks based on combined scores from four different forensic algorithms. Both the 2022 January Positive Forensic portfolio beat the S&P 500 by +6.59% and the Negative For...

ITOS - New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

2023-06-08 12:15:22 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – June 8, 2023 – USA News Group –  By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle aga...

ITOS - iTeos Therapeutics: Trading Under Cash Value

2023-06-04 10:04:13 ET Summary Today, we circle back on small oncology concern iTeos Therapeutics, Inc. for the first time since last July. The company is advancing its two primary compounds in its pipeline and has a potentially lucrative partnership with GlaxoSmithKline. The ...

ITOS - iTeos Therapeutics GAAP EPS of -$0.44

2023-05-10 08:58:59 ET iTeos Therapeutics press release ( NASDAQ: ITOS ): Q1 GAAP EPS of -$0.44. The company’s cash, cash equivalents, and investments position was $706.6 million as of March 31, 2023, as compared to $824.0 million as of March 31, 2022. Research ...

Previous 10 Next 10